These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23469669)

  • 1. [Advances in the studies of refractory erectile dysfunction].
    Wang BY; Jiang R
    Zhonghua Nan Ke Xue; 2013 Jan; 19(1):82-5. PubMed ID: 23469669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction.
    Jenkins LC; Hall M; Deveci S; Guhring P; Parker M; Nelson CJ; Mulhall JP
    J Sex Med; 2019 Oct; 16(10):1541-1546. PubMed ID: 31444103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on drug interactions with phosphodiesterase-5 inhibitors prescribed as first-line therapy for patients with erectile dysfunction or pulmonary hypertension.
    Gur S; Kadowitz PJ; Gokce A; Sikka SC; Lokman U; Hellstrom WJ
    Curr Drug Metab; 2013 Feb; 14(2):265-9. PubMed ID: 23140258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Carson CC; Lue TF
    BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes.
    Park K; Cho SY; Kim SW
    Int J Androl; 2011 Oct; 34(5 Pt 2):e468-74. PubMed ID: 21790657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction.
    Megas G; Papadopoulos G; Stathouros G; Moschonas D; Gkialas I; Ntoumas K
    BJU Int; 2013 Jul; 112(2):E169-76. PubMed ID: 23253640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States.
    Nunes AP; Seeger JD; Stewart A; Gupta A; McGraw T
    J Sex Med; 2021 Sep; 18(9):1511-1523. PubMed ID: 34389264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Vardenafil for refractory erectile dysfunction: the latest advances].
    Wang HY; Huang YF
    Zhonghua Nan Ke Xue; 2009 Nov; 15(11):1035-8. PubMed ID: 20218319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE5 inhibitors: targeting erectile dysfunction in diabetics.
    Francis SH; Corbin JD
    Curr Opin Pharmacol; 2011 Dec; 11(6):683-8. PubMed ID: 21924956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update].
    Jiang R
    Zhonghua Nan Ke Xue; 2013 Mar; 19(3):195-8. PubMed ID: 23700721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does testosterone supplementation increase PDE5-inhibitor responses in difficult-to-treat erectile dysfunction patients?
    Aversa A; Francomano D; Lenzi A
    Expert Opin Pharmacother; 2015 Apr; 16(5):625-8. PubMed ID: 25643866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erectile dysfunction and diabetes: a review of the current evidence-based medicine and a synthesis of the main available therapies.
    Phé V; Rouprêt M
    Diabetes Metab; 2012 Feb; 38(1):1-13. PubMed ID: 22056307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
    Liu DF; Jiang H; Hong K; Zhao LM; Tang WH; Ma LL
    Chin Med J (Engl); 2010 Nov; 123(22):3258-61. PubMed ID: 21163126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
    Dorsey P; Keel C; Klavens M; Hellstrom WJ
    Expert Opin Pharmacother; 2010 May; 11(7):1109-22. PubMed ID: 20402554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?].
    Baydaroglu E; Eschwège P; Hubert J; El Osta R
    Prog Urol; 2019; 29(6):326-331. PubMed ID: 31151915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management of erectile dysfunction: innovations and future perspectives.
    Leonardi R; Alemanni M
    Arch Ital Urol Androl; 2011 Mar; 83(1):60-2. PubMed ID: 21585174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erectile dysfunction and cardiovascular disease.
    Menezes A; Artham S; Lavie CJ; Milani RV; O'Keefe J
    Postgrad Med; 2011 May; 123(3):7-16. PubMed ID: 21566411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential for Long-Term Benefit of Cognitive Behavioral Therapy as an Adjunct Treatment for Men with Erectile Dysfunction.
    Khan S; Amjad A; Rowland D
    J Sex Med; 2019 Feb; 16(2):300-306. PubMed ID: 30770073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy.
    Kimura M; Caso JR; Bañez LL; Koontz BF; Gerber L; Senocak C; Donatucci CF; Vujaskovic Z; Moul JW; Polascik TJ
    BJU Int; 2012 Dec; 110(11 Pt C):E931-8. PubMed ID: 22520165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.